

Muhammad Abdul-Ghani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9019106/muhammad-abdul-ghani-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191
papers

44,918
citations

90
h-index

202
g-index

202
ext. papers

49,192
ext. citations

8.6
avg, IF

7.76
L-index

#	Paper	IF	Citations
191	Comprehensive analysis of circulating miRNA expression profiles in insulin resistance and type 2 diabetes in Qatari population 2022 , 15, 191-202		
190	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.. <i>Diabetes Care</i> , 2022 ,	14.6	1
189	Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. <i>Diabetes</i> , 2021 , 70, 1303-1316	0.9	3
188	Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2022-2039	15.1	7
187	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1631-1639	6.7	1
186	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , 2021 , 70, 204-213	0.9	4
185	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. <i>Diabetes</i> , 2021 , 70, 377-385	0.9	17
184	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. <i>Diabetes Care</i> , 2021 , 44, 433-439	14.6	7
183	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021 , 114, 154416	12.7	6
182	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , 2021 , 17, 319-334	14.9	59
181	Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1398-1409	5.6	4
180	Insulin Resistance and Hyperinsulinemia: the Egg and the Chicken. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1897-e1899	5.6	3
179	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , 2021 , 44, 1062-1069	14.6	9
178	Preface: Cardiorenal Considerations for Type 2 Diabetes-Time to Exit the Dark Ages. <i>Diabetes Spectrum</i> , 2021 , 34, 214-215	1.9	
177	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2113-2125	4	
176	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <i>Diabetes Spectrum</i> , 2021 , 34, 225-234	1.9	0
175	Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3497-3504	5.6	0

174	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. <i>Diabetes</i> , 2020 , 69, 681-688	0.9	11
173	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA _{1c} , in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1234-1241	14.6	18
172	Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 99-106	6.7	3
171	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , 2020 , 43, 2519-2527	14.6	1
170	Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2287-2294	6.7	2
169	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA _{1c} with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
168	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020 , 63, 2423-2433	10.3	7
167	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , 2019 , 40, 1447-1467	27.2	85
166	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 133-143	3.3	63
165	Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2842-2850	5.6	11
164	Exenatide modulates visual cortex responses. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e31675	6.7	1
163	The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. <i>Nature Communications</i> , 2019 , 10, 4720	17.4	7
162	Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. <i>BMC Endocrine Disorders</i> , 2019 , 19, 87	3.3	4
161	Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2019 , 17, 153-163	3.3	22
160	Glucose-Mediated Glucose Disposal at Baseline Insulin Is Impaired in IFG. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 163-171	5.6	7
159	Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 705-709	6.7	1
158	Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00014	2.7	3
157	Empagliflozin Treatment Is Associated With Improved βCell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1402-1407	5.6	33

156	Slope of change in HbA from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00016	2.7	5
155	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. <i>Diabetes</i> , 2018 , 67, 1182-1189	0.9	36
154	Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018 , 315, E229-E239	6	10
153	Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1075-1079	6.7	6
152	Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00034	2.7	5
151	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose \geq 55 mg/dl (8.6 mmol/L). <i>Diabetes Research and Clinical Practice</i> , 2018 , 146, 18-33	7.4	44
150	Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. <i>Diabetes</i> , 2018 , 67, 2507-2517	0.9	18
149	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. <i>Diabetes Care</i> , 2017 , 40, 325-331	14.6	26
148	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. <i>Diabetes</i> , 2017 , 66, 815-822	0.9	152
147	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 809-813	6.7	44
146	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2017 , 66, 1999-2006	0.9	38
145	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1353-1362	6.7	88
144	Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1322-1326	6.7	56
143	Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2162-2170	5.6	8
142	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017 , 40, 813-820	14.6	78
141	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β Cell Function in Subjects With Impaired Fasting Glucose. <i>Diabetes</i> , 2017 , 66, 2495-2502	0.9	12
140	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2017 , 23, 207-238	3.2	302
139	Impact of ethnicity and obesity on insulin resistance in two ethnic groups at very high risk of type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017 , 43, 292-294	5.4	3

138	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , 2017 , 13, 11-26	14.9	265
137	Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. <i>FEBS Journal</i> , 2017 , 284, 451-465	5.7	15
136	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1530-1536	14.6	34
135	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , 2017 , 40, 1121-1127	14.6	32
134	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , 2016 , 39, 198-205	14.6	182
133	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 2036-2041	14.6	105
132	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 454-62	6.7	34
131	Diverted sleeve gastrectomy with ileal transposition in overweight, obese, and morbidly obese patients with type 2 diabetes: results of 1-year follow-up. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 541-549	3	7
130	Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2016 , 19, 394-399	3.8	26
129	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , 2016 , 59, 1645-54	10.3	67
128	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016 , 39, 717-25	14.6	211
127	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. <i>Diabetes Care</i> , 2016 , 39, 1804-10	14.6	10
126	Dapagliflozin lowers plasma glucose concentration and improves Ecell function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1927-32	5.6	97
125	Combination therapy in type 2 diabetes mellitus 2015 , 686-708		1
124	Fiber orientation measurements by diffusion tensor imaging improve hydrogen-1 magnetic resonance spectroscopy of intramyocellular lipids in human leg muscles. <i>Journal of Medical Imaging</i> , 2015 , 2, 026002	2.6	3
123	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, F889-900	4.3	82
122	Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 268-75	6.7	115
121	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15019	51.1	651

120	Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. <i>Diabetes Care</i> , 2015 , 38, 384-93	14.6	210
119	What are the pharmacotherapy options for treating prediabetes?. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2003-18	4	20
118	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014 , 124, 509-14	15.9	514
117	Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 239-43	4.4	5
116	The disposition index does not reflect β cell function in IGT subjects treated with pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3774-81	5.6	25
115	Strong association between insulin-mediated glucose uptake and the 2-hour, not the fasting plasma glucose concentration, in the normal glucose tolerance range. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3444-9	5.6	7
114	Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. <i>Diabetes</i> , 2013 , 62, 3920-60.9		68
113	Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. <i>Diabetes Care</i> , 2013 , 36, 2756-62	14.6	43
112	Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. <i>Nutrients</i> , 2013 , 5, 1544-60	6.7	474
111	Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 393-9	9.4	78
110	Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. <i>Hospital Practice (1995)</i> , 2013 , 41, 132-47	2.2	20
109	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S162-74	14.6	72
108	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 3169-76	14.6	193
107	Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. <i>Diabetes</i> , 2013 , 62, 3324-8	0.9	163
106	Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1615-22	5.6	78
105	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 5-14	6.7	342
104	Distinct β cell defects in impaired fasting glucose and impaired glucose tolerance. <i>Diabetes</i> , 2012 , 61, 447-53	0.9	88
103	Pioglitazone for diabetes prevention in impaired glucose tolerance. <i>New England Journal of Medicine</i> , 2011 , 364, 1104-15	59.2	537

102	Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. <i>Acta Diabetologica</i> , 2011 , 48, 209-17	3.9	46
101	Preservation of β -cell function: the key to diabetes prevention. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2354-66	5.6	182
100	Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1763-70	5.6	41
99	The relationship between β -cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. <i>Diabetes Care</i> , 2011 , 34, 1006-10	14.6	52
98	Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. <i>Endocrine Reviews</i> , 2011 , 32, 515-31	27.2	292
97	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. <i>Diabetic Medicine</i> , 2010 , 27, 309-17	3.5	158
96	Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. <i>Diabetes Care</i> , 2010 , 33, 951-7	14.6	90
95	Pathogenesis of insulin resistance in skeletal muscle. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 476279		325
94	Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1916-23	5.6	64
93	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. <i>Diabetologia</i> , 2010 , 53, 1270-87	10.3	573
92	Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. <i>Diabetologia</i> , 2009 , 52, 723-32	10.3	105
91	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. <i>Diabetes</i> , 2009 , 58, 773-95	0.9	1832
90	Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 1204-11	6.7	61
89	Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. <i>Diabetes</i> , 2008 , 57, 2595-602	0.9	279
88	Insulin reduces plasma arginase activity in type 2 diabetic patients. <i>Diabetes Care</i> , 2008 , 31, 134-9	14.6	83
87	Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. <i>Diabetes Care</i> , 2008 , 31, 311-5	14.6	29
86	The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E401-6	6	57
85	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 294, E846-52	6	132

84	Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 294, E910-7	6	63
83	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2943-52	2.5	321
82	Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. <i>Gastroenterology</i> , 2007 , 133, 496-506	13.3	397
81	Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 275-81	6.1	71
80	Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2007 , 50, 1723-31	10.3	107
79	Thiazolidinediones improve beta-cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 292, E871-83	6	145
78	Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. <i>Diabetes/Metabolism Research and Reviews</i> , 2006 , 22, 423-36	7.5	301
77	The effect of pioglitazone on the liver: role of adiponectin. <i>Diabetes Care</i> , 2006 , 29, 2275-81	14.6	67
76	Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. <i>Diabetes</i> , 2006 , 55, 760-7	0.9	104
75	Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , 2006 , 55, 1430-5	0.9	384
74	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. <i>New England Journal of Medicine</i> , 2006 , 355, 2297-307	59.2	1311
73	Comprehensive assessment of postischemic vascular reactivity in Hispanic children and adults with and without diabetes mellitus. <i>Pediatric Diabetes</i> , 2006 , 7, 329-35	3.6	12
72	Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. <i>Diabetes Care</i> , 2006 , 29, 1130-9	14.6	262
71	Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. <i>Diabetes</i> , 2005 , 54, 3148-53	0.9	146
70	beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 493-500	5.6	407
69	Dose-response effect of elevated plasma free fatty acid on insulin signaling. <i>Diabetes</i> , 2005 , 54, 1640-8	0.9	288
68	Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1100-5	5.6	107
67	Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. <i>Journal of Biological Chemistry</i> , 2005 , 280, 10290-7	5.4	191

66	A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. <i>Archives of Internal Medicine</i> , 2004 , 164, 2097-104		224
65	Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 200-6	5.6	305
64	Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004 , 287, E537-46	6	75
63	Dysfunctional fat cells, lipotoxicity and type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2004 , 58, 9-21	2.9	148
62	Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. <i>Diabetologia</i> , 2004 , 47, 31-9	10.3	257
61	Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 463-78	5.6	492
60	Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. <i>Diabetes</i> , 2003 , 52, 1364-70	0.9	240
59	A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. <i>Diabetes</i> , 2003 , 52, 2461-74	0.9	388
58	Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. <i>Diabetologia</i> , 2003 , 46, 1211-9	10.3	89
57	Metabolic and molecular basis of insulin resistance. <i>Journal of Nuclear Cardiology</i> , 2003 , 10, 311-23	2.1	83
56	Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8466-71	11.5	1595
55	Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. <i>Diabetes</i> , 2003 , 52, 1943-50	0.9	116
54	Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2784-91	5.6	554
53	Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. <i>Diabetes</i> , 2002 , 51, 3043-8	0.9	36
52	Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. <i>Metabolism: Clinical and Experimental</i> , 2002 , 51, 1111-9	12.7	67
51	Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. <i>Diabetologia</i> , 2001 , 44, 2210-9	10.3	236
50	Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. <i>Diabetes</i> , 2001 , 50, 2572-8	0.9	86
49	Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. <i>Diabetes Care</i> , 2001 , 24, 710-9	14.6	335

48	Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001 , 280, E712-9	6	41
47	Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. <i>Journal of Clinical Investigation</i> , 2000 , 105, 311-20	15.9	812
46	Bromocriptine: a novel approach to the treatment of type 2 diabetes. <i>Diabetes Care</i> , 2000 , 23, 1154-61	14.6	176
45	Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. <i>Diabetes Care</i> , 1999 , 22, 1462-70	14.6	4139
44	Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. <i>Metabolism: Clinical and Experimental</i> , 1999 , 48, 330-7	12.7	36
43	Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. <i>Netherlands Journal of Medicine</i> , 1997 , 50, 191-7	0.5	199
42	UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues. <i>Diabetologia</i> , 1997 , 40, 76-81	10.3	41
41	Insulin resistance and coronary artery disease. <i>Diabetologia</i> , 1996 , 39, 1345-50	10.3	153
40	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 4059-67	5.6	306
39	Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. <i>Diabetes</i> , 1996 , 45, 302-7	0.9	99
38	Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance. <i>Journal of the Society for Gynecologic Investigation</i> , 1995 , 2, 708-715		27
37	Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>New England Journal of Medicine</i> , 1995 , 333, 541-9	59.2	1049
36	Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. <i>Journal of the Society for Gynecologic Investigation</i> , 1995 , 2, 708-15		31
35	Comparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humans. <i>Diabetologia</i> , 1995 , 38, 732-738	10.3	
34	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. <i>Diabetologia</i> , 1994 , 37, 1025-35	10.3	248
33	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man 1994 , 37, 1025		4
32	The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. <i>Diabetes</i> , 1992 , 41, 1575-86	0.9	247
31	Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women. <i>Diabetes</i> , 1992 , 41, 1151-1159	0.9	140

30	Insulin resistance, hypertension and cellular ion transport systems. <i>Acta Diabetologica</i> , 1992 , 29, 196-200.	3.9	5
29	Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 1294-301	5.6	317
28	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. <i>Diabetes Care</i> , 1991 , 14, 173-94	14.6	3010
27	Differential effect of hyperglycemia and hyperinsulinemia on pathways of hepatic glycogen repletion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1991 , 260, E731-5	6	9
26	Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. <i>Journal of Clinical Investigation</i> , 1991 , 87, 561-70	15.9	126
25	Indirect calorimetry: methodological and interpretative problems. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1990 , 258, E399-412	6	126
24	Glucose toxicity. <i>Diabetes Care</i> , 1990 , 13, 610-30	14.6	817
23	Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by ¹³ C nuclear magnetic resonance spectroscopy. <i>New England Journal of Medicine</i> , 1990 , 322, 223-8	59.2	1052
22	Obesity and insulin resistance in humans: a dose-response study. <i>Metabolism: Clinical and Experimental</i> , 1990 , 39, 452-9	12.7	290
21	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 387-95	12.7	451
20	Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1989 , 257, E241-6	6	62
19	Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. <i>Journal of Clinical Investigation</i> , 1989 , 84, 205-13	15.9	585
18	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , 1988 , 37, 79-85	12.7	235
17	Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. <i>Diabetes</i> , 1988 , 37, 667-87	0.9	2174
16	Effect of physical training on insulin action in obesity. <i>Diabetes</i> , 1987 , 36, 1379-85	0.9	132
15	Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. <i>Diabetes</i> , 1987 , 36, 1341-50	0.9	235
14	Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. <i>Journal of Clinical Investigation</i> , 1987 , 79, 1510-5	15.9	606
13	Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. <i>Journal of Clinical Investigation</i> , 1987 , 80, 1037-44	15.9	264

12	Physical training and insulin sensitivity. <i>Diabetes/metabolism Reviews</i> , 1986 , 1, 445-81		176
11	Effect of insulin on the distribution and disposition of glucose in man. <i>Journal of Clinical Investigation</i> , 1985 , 76, 357-64	15.9	194
10	Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. <i>Journal of Clinical Investigation</i> , 1985 , 76, 149-55	15.9	799
9	Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. <i>Diabetes</i> , 1983 , 32, 35-45	0.9	499
8	Insulin secretion, insulin resistance, and obesity 1982 , 6 Suppl 1, 73-82		14
7	Glucose intolerance and aging. <i>Diabetes Care</i> , 1981 , 4, 493-501	14.6	284
6	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , 1980 , 29, 28-35	12.7	109
5	Glucose clamp technique: a method for quantifying insulin secretion and resistance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1979 , 237, E214-23	6	2392
4	Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978 , 75, 5173-7	11.5	250
3	Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. <i>Journal of Clinical Investigation</i> , 1978 , 62, 204-13	15.9	180
2	A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. <i>Diabetes</i> , 1977 , 26, 445-52	0.9	66
1	The effects of glucose and insulin on renal electrolyte transport. <i>Journal of Clinical Investigation</i> , 1976 , 58, 83-90	15.9	320